{"nctId":"NCT00884585","briefTitle":"Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis","startDateStruct":{"date":"2009-05"},"conditions":["Atopic Conjunctivitis"],"count":176,"armGroups":[{"label":"Cyclosporine Ophthalmic Solution (COS) followed by COS","type":"EXPERIMENTAL","interventionNames":["Drug: Cyclosporine 0.010%"]},{"label":"Placebo followed by COS","type":"OTHER","interventionNames":["Drug: Cyclosporine Vehicle","Drug: Cyclosporine 0.010%"]}],"interventions":[{"name":"Cyclosporine Vehicle","otherNames":[]},{"name":"Cyclosporine 0.010%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a clinical diagnosis of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye)\n* Be on stable doses of your current AKC medications for at least 2 weeks\n\nExclusion Criteria:\n\n* You have used contact lenses within 48 hours of Day 1 or think you may have to wear contact lenses during the study\n* You are pregnant, breastfeeding, or planning to become pregnant during the study\n* You have used a calcineurin inhibitors (e.g. topical tacrolimus or topical pimecrolimus) on or around your eyes including eyelids within 4 weeks","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Treatment Responders","description":"Treatment responders are defined as patients with a ≥ 1 grade improvement from baseline in punctate corneal staining score and a ≥ 4 grade improvement from baseline in composite symptom score in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 (0 is ≤2 dots and 5 is \\>316 dots (approximately) or ulcer/erosion). The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). The composite symptom score (0 to 15) is the sum of 5 symptoms (each symptom is assessed on a scale of 0=absent to 3=severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"17.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Punctate Corneal Staining Responders","description":"Punctate corneal staining responders defined as patients achieving a punctate corneal staining score of 0 or 1 in the study eye. Punctate corneal staining is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \\>2 dots but ≤ 10 dots, 2 is \\> 10 dots but ≤ 32 dots, 3 is \\> 32 dots but ≤ 100 dots (approximately), 4 is \\> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \\>316 dots (approximately) or ulcer/erosion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With an Improvement in the Composite Symptom Score","description":"Composite symptom score improvement is defined as a 4 or more grade decrease from baseline in composite symptom score in the study eye. The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). Each of the 5 symptoms is assessed on a scale of 0=absent to 3=severe. The composite symptom score is the sum of all 5 individual symptom scores, where 0 is no symptoms and 15 is the most severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"28.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With an Improvement in the Punctate Corneal Staining Score","description":"Punctate corneal staining improvement is defined as a 1 or more grade decrease from baseline in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \\>2 dots but ≤ 10 dots, 2 is \\> 10 dots but ≤ 32 dots, 3 is \\> 32 dots but ≤ 100 dots (approximately), 4 is \\> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \\>316 dots (approximately) or ulcer/erosion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":null},{"groupId":"OG001","value":"42.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":171},"commonTop":["Allergic Keratitis","Blepharitis","Punctate Keratitis"]}}}